Biohaven dropped 44% in premarket trading after the FDA declined to approve Vyglxia, citing issues with trial design even as ...

Axon shares dropped 20% after reporting a Q3 profit miss tied to tariff costs, though revenue exceeded forecasts at $710.6 ...

McDonald's Q3 2025 results showed a 3.6% rise in global sales, while EPS of $3.18 came in just below forecasts.

Emerson’s Q4 2025 results showed steady growth, with EPS meeting expectations and revenue slightly below estimates.

Humana’s third-quarter results beat expectations with adjusted EPS of $3.24 and revenue of $32.65 billion, as the company ...

Denny’s stock surged 46% in premarket trading after agreeing to a $620 million take-private deal with TriArtisan Capital ...

Uber’s third-quarter performance exceeded forecasts, highlighting solid growth and continued confidence in its outlook for ...

Palantir stock fell 8% in premarket trading despite beating Q3 estimates and raising guidance, as valuation concerns and ...

Pfizer reported Q3 2025 revenue of $16.7 billion and adjusted EPS of $0.87, beating expectations and prompting a full-year ...

Eaton Corporation plc (NYSE: ETN) reported record results for the third quarter of 2025, driven by strong order growth and ...

Shopify exceeded Q3 expectations with $2.84 billion in revenue and solid earnings performance, reinforcing confidence in its ...

Michael Burry’s sizable put options on PLTR suggest cautious skepticism, even as the stock’s memetic narrative fuels ...